Abivax announces late-breaking presentation of 8-week abtect trial results with updated safety data

Abivax announces late-breaking presentation of 8-week abtect trial results with updated safety data 50 mg once-daily dose of obefazimod led to a pooled 16.4% (p

ABVX Ratings Summary

ABVX Quant Ranking